snyderman nancy lynn MD
Known title: DirectorCIK: 0001675198
snyderman nancy lynn MD's purchase track record
snyderman nancy lynn MD has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2022 | ALKS | $10K | +26.5% | +5.7% | -9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALKS | ▲ Buy | Option Exercise | 27,948 | $1.3M | 8/3/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 16,524 | $772K | 8/3/2026 | View on chart |
| ALKS | ▼ Sell | Open Market | 44,472 | $2.2M | 8/3/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,142 | — | 5/21/2026 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,475 | $55K | 5/21/2026 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 8,013 | — | 5/31/2025 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,924 | $59K | 5/31/2025 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 6,104 | — | 6/29/2024 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,465 | $35K | 6/29/2024 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,957 | — | 7/7/2023 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,430 | $43K | 7/7/2023 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 7,585 | — | 6/14/2022 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 695 | $19K | 6/14/2022 | View on chart |
| ALKS | ▲ Buy | Open Market | 427 | $10K | 3/4/2022 | View on chart |
| ALKS | ▲ Buy | Option Exercise | 5,578 | — | 12/2/2021 | View on chart |
| ALKS | ▼ Sell | Tax Withholding | 1,339 | $30K | 12/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Baird Highlights Growth Potential for Alkermes plc (ALKS)
Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.
Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.